Latest Period
Q1 2026
Security Snapshot
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) Institutional Ownership
CUSIP: 00461U105
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
135
Shares (Excl. Options)
109,211,572
Price
$3.75
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Symbol
- ACRS on Nasdaq
- Shares outstanding
- 138,752,791
- Reported price per share
- $4.93
- Price from insider filings
- $4.93
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 109,211,572
- Total reported value
- $409,401,104
- Portfolio coverage rank
- 0%
- Share change
- +26,160,441
- Value change
- +$98,847,452
- Number of holders
- 135
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 00461U105.
- 135 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 122 to 135 between Q4 2025 and Q1 2026.
- Reported value moved from $252,051,598 to $409,401,104.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 135 institutions filings for Q1 2026.
Security key
00461U105
Latest holder period
Q1 2026
13F holders
135
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
ACRS full holder history
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Aclaris Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00461U105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ACRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | -17% | $52,312,500 | -$1,125,000 | 13,950,000 | -2.1% | BML Investment Partners, L.P. | 23 Apr 2026 |
| Bonita Biotech (HK) Ltd | 9.4% | $33,944,003 | 11,281,950 | Biosion, Inc. | 09 Dec 2025 | |||
| Deep Track Capital, LP | 7% | $33,735,450 | 9,345,000 | Deep Track Capital, LP | 09 Mar 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 6.3% | $28,600,144 | 7,626,705 | RA Capital Management, L.P. | 31 Mar 2026 | |||
| BlackRock, Inc. | 6.2% | +22% | $20,164,873 | +$3,698,306 | 6,700,629 | +22% | BlackRock, Inc. | 31 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 4.3% | $22,373,888 | 5,966,370 | Vivo Opportunity Fund Holdings, L.P. | 31 Mar 2026 | |||
| Adage Capital Management, L.P. | 4.9% | -34% | $10,028,474 | -$5,554,080 | 5,278,144 | -36% | Adage Capital Management, L.P. | 30 Sep 2025 |
| Rock Springs Capital Management LP | 4.7% | $7,720,853 | 5,046,309 | Rock Springs Capital Management LP | 31 Mar 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.5% | -32% | $5,449,080 | -$2,422,176 | 3,837,380 | -31% | Millennium Management LLC | 30 Jun 2025 |
As of 31 Mar 2026, 135 institutional investors reported holding 109,211,572 shares of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS). This represents 79% of the company’s total 138,752,791 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 10% | 14,250,000 | 0% | 34% | $53,437,500 |
| Deep Track Capital, LP | 6.7% | 9,345,000 | 0.72% | $35,043,750 | |
| BlackRock, Inc. | 5.3% | 7,407,065 | +8.8% | 0% | $27,776,494 |
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | 6,804,072 | 0.27% | $25,515,270 | |
| Vivo Capital, LLC | 4.8% | 6,666,666 | -25% | 2.1% | $24,999,998 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 5,167,469 | 0% | 0% | $19,378,009 |
| Frazier Life Sciences Management, L.P. | 3.5% | 4,925,374 | 0.48% | $18,470,153 | |
| Rock Springs Capital Management LP | 3.2% | 4,472,650 | +0.42% | 0.99% | $16,772,438 |
| Decheng Capital LLC | 2.9% | 4,041,736 | 0% | 2.3% | $15,156,510 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8% | 3,871,000 | +15% | 0.02% | $14,516,250 |
| Balyasny Asset Management L.P. | 2.4% | 3,361,328 | 0.02% | $12,604,980 | |
| MORGAN STANLEY | 2% | 2,746,302 | -20% | 0% | $10,298,633 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 2,423,691 | +1.3% | 0% | $9,091,533 |
| CITADEL ADVISORS LLC | 1.6% | 2,249,319 | +87% | 0.01% | $8,434,946 |
| STATE STREET CORP | 1.4% | 2,008,746 | +33% | 0% | $7,532,798 |
| Kalehua Capital Management LLC | 1.3% | 1,832,365 | 4.9% | $6,871,369 | |
| BRAIDWELL LP | 1.2% | 1,699,116 | 0.21% | $6,371,685 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 1,656,066 | 0% | 0% | $6,210,248 |
| Palo Alto Investors LP | 1.2% | 1,613,430 | +3% | 0.93% | $6,050,363 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 1,539,791 | -27% | 0.01% | $5,770,000 |
| Woodline Partners LP | 1.1% | 1,485,623 | +100% | 0.02% | $5,571,086 |
| Connor, Clark & Lunn Investment Management Ltd. | 1% | 1,418,360 | -1.1% | 0.01% | $5,318,850 |
| DEUTSCHE BANK AG\ | 0.72% | 997,850 | +1.1% | 0% | $3,741,938 |
| Aldebaran Capital, LLC | 0.68% | 947,162 | -0.74% | 2.7% | $3,551,858 |
| D. E. Shaw & Co., Inc. | 0.65% | 900,804 | -57% | 0% | $3,378,015 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q1 2026
Rows shown
1-25 of 42
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 109,211,572 | $409,401,104 | +$98,847,452 | $3.75 | 135 |
| 2025 Q4 | 83,739,024 | $252,051,598 | -$10,906,407 | $3.01 | 122 |
| 2025 Q3 | 85,675,311 | $162,782,120 | -$11,317,612 | $1.90 | 103 |
| 2025 Q2 | 91,862,480 | $130,443,350 | -$2,093,251 | $1.42 | 95 |
| 2025 Q1 | 92,164,636 | $141,009,418 | +$2,108,864 | $1.53 | 106 |
| 2024 Q4 | 87,478,919 | $216,988,373 | +$93,728,957 | $2.48 | 97 |
| 2024 Q3 | 50,891,008 | $58,523,068 | -$1,742,222 | $1.15 | 76 |
| 2024 Q2 | 52,848,132 | $58,129,308 | -$1,619,597 | $1.10 | 93 |
| 2024 Q1 | 54,386,842 | $67,436,941 | -$3,788,067 | $1.24 | 93 |
| 2023 Q4 | 58,449,543 | $61,369,526 | -$207,123,774 | $1.05 | 102 |
| 2023 Q3 | 70,071,814 | $479,974,125 | -$28,113,579 | $6.85 | 137 |
| 2023 Q2 | 71,014,841 | $736,442,996 | +$5,835,766 | $10.37 | 131 |
| 2023 Q1 | 71,610,627 | $579,302,266 | +$19,605,105 | $8.09 | 148 |
| 2022 Q4 | 65,900,596 | $1,037,946,141 | -$2,542,115 | $15.75 | 126 |
| 2022 Q3 | 63,675,444 | $1,002,225,041 | +$5,530,098 | $15.74 | 124 |
| 2022 Q2 | 63,269,555 | $883,318,693 | +$55,162,166 | $13.96 | 112 |
| 2022 Q1 | 59,295,213 | $1,021,908,185 | +$59,352,437 | $17.24 | 107 |
| 2021 Q4 | 56,045,310 | $814,890,981 | -$39,784,690 | $14.54 | 133 |
| 2021 Q3 | 56,785,960 | $1,022,155,424 | +$15,328,009 | $18.00 | 126 |
| 2021 Q2 | 56,004,936 | $983,410,407 | +$20,628,850 | $17.56 | 128 |
| 2021 Q1 | 45,417,666 | $1,298,594,000 | +$509,363,836 | $25.20 | 95 |
| 2020 Q4 | 31,934,018 | $206,591,000 | +$27,717,112 | $6.47 | 79 |
| 2020 Q3 | 25,553,008 | $65,673,000 | -$3,889,513 | $2.57 | 52 |
| 2020 Q2 | 28,456,883 | $46,099,261 | -$5,512,533 | $1.62 | 56 |
| 2020 Q1 | 32,079,500 | $33,361,056 | +$3,161,589 | $1.04 | 65 |